Kala Bio Inc (KALA) Stock Price, Quote & News

Company Profile

KALA BIO, Inc., a biopharmaceutical company, engages in the development of an on-premises artificial intelligence (AI) infrastructure platform for biotechnology research applications in the United States. The company develops Researgency, an agentic AI research platform for private enterprise AI deployment. Its platform intends to utilize the KPI-012 clinical development dataset as a proof-of-concept validation environment, as well as the mesenchymal stem cell secretome (MSC-S) and persistent co...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 996 5252

Website: www.kalarx.com

Address:

1167 Massachusetts Avenue, Arlington, United States

MrTicker Sep. 1 at 9:52 PM

$KALA earlier news if you missed it: Kala Bio and Virotek Announce Letter of Intent to Establish an Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program GLOBENEWSWIRE 6:45 AM ET 9/1/2026

0 · Reply

MrTicker Sep. 1 at 9:51 PM

$KALA on the move

0 · Reply

RTPRwire Sep. 1 at 9:36 PM

Today's biggest catalyst moves on the wire (validated intraday captures through 5:15 PM ET): $BIAF ran as much as +89% — product launch $OLOX ran as much as +49% — product launch $MIRA ran as much as +39% — clinical trial results $KALA ran as much as +37% — partnership $AMBR ran as much as +31% — product launch Get real-time catalyst alerts using RTPR.

0 · Reply

Nibbler Sep. 1 at 6:13 PM

$KALA Why it is down?

0 · Reply

Gymlover Sep. 1 at 3:58 PM

$KALA it’s going to short squeeze 👀 👀

1 · Reply

Kennyk93 Sep. 1 at 2:38 PM

$KALA added

0 · Reply

Ozyil Sep. 1 at 2:34 PM

$KALA i forgot buy dip at opening, i will wait for next dip

0 · Reply

SwingTrader34 Sep. 1 at 1:19 PM

$KALA seems like they will dump it today. i am out with a small loss

0 · Reply

SwingTrader34 Sep. 1 at 12:52 PM

$KALA These mfers are so greedy that they don't let go any opportunity to dilute the shareholders.

0 · Reply

Skimman Sep. 1 at 12:48 PM

$KALA Bullshit Company

0 · Reply

Kala Bio, Virotek enters LOI for distribution agreement

Sep 1, 2026, 7:45 AM EDT - 13 hours ago

Kala Bio and Virotek Announce Letter of Intent to Establish an Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program

Aug 19, 2026, 7:00 AM EDT - 13 days ago

KALA BIO Quarterly report: Q2 2026

Jun 12, 2026, 8:00 AM EDT - 2 months ago

KALA BIO Registration statement: Registration filing

May 15, 2026, 7:00 AM EDT - 3 months ago

KALA BIO Quarterly report: Q1 2026

2026-05-12T17:59:22.000Z - 4 months ago

Kala Bio falls -21.7%

2026-05-07T22:27:13.000Z - 4 months ago

Kala Bio files $350M mixed securities shelf

2026-05-07T18:28:35.000Z - 4 months ago

Kala Bio announces reverse stock split

May 7, 2026, 9:00 AM EDT - 4 months ago

KALA BIO Announces Reverse Stock Split

May 7, 2026, 8:00 AM EDT - 4 months ago

KALA BIO Registration statement: Registration filing

2026-04-21T12:34:59.000Z - 4 months ago

Kala Bio ‘celebrates’ U.S. Executive Order for psychedelic medicine

Apr 21, 2026, 7:00 AM EDT - 4 months ago

Kala Bio Celebrates Trump Executive Order as Game-Changer for Psychedelic Medicine

Apr 15, 2026, 7:00 AM EDT - 4 months ago

KALA BIO Annual report: Q4 2025

Apr 1, 2026, 6:45 AM EDT - 5 months ago

Kala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and Precision Development Opportunities

Mar 30, 2026, 8:45 AM EDT - 5 months ago

KALA BIO Delivers Industry-Leading AI Infrastructure: Bionic Intelligence Research Agent Now Live

2026-03-18T13:05:59.000Z - 5 months ago

Red Light Holland engages Kala Bio with its Researgency.ai platform

Mar 18, 2026, 9:00 AM EDT - 5 months ago

Red Light Holland Engages Kala Bio's Researgency.AI Platform to Support Clinical Development of Filament's Patented PEX010 Botanical Psilocybin Drug Candidate

Mar 18, 2026, 8:15 AM EDT - 5 months ago

Red Light Holland Engages Kala Bio's Researgency.ai Platform to Support Clinical Development of Filament Health's Patented PEX010 Botanical Psilocybin Drug Candidate

Mar 11, 2026, 11:18 AM EDT - 6 months ago

Younet.ai Highlights Researgency.ai Collaboration with Kala Bio (KALA) as New "AutoResearch" Milestone Signals the Rise of Autonomous Research Agents

2026-03-11T12:00:18.000Z - 6 months ago

KALA BIO Stock Rockets on Plans to Become the ‘Palantir for Biotech’

PLTR

2026-03-11T10:40:33.000Z - 6 months ago

Kala Bio poised to ship first commercial AI product in about 14 days

Mar 11, 2026, 6:30 AM EDT - 6 months ago

Kala Bio Launches a Revolution for Biotech- First AI Agent Deploying in 14 Days as $180 Billion Agentic AI Healthcare Revolution Accelerates

2026-03-04T11:45:29.000Z - 6 months ago

Kala Bio announces initiative to build AI infrastructure platform

Mar 4, 2026, 6:30 AM EST - 6 months ago

KALA BIO Announces Strategic Initiative to Deploy and Continue to Develop an On-Premises AI Infrastructure Platform for the Biotech Industry; Enters Into Platform Development and Exclusive License Agreement for Proprietary AI Research Platform “Researgency”

Feb 10, 2026, 7:00 AM EST - 7 months ago

KALA BIO Registration statement: Registration Filing

2026-02-10T11:15:48.000Z - 7 months ago

Kala Bio files to sell 241.44M shares of common stock for holders

Jan 30, 2026, 11:00 AM EST - 7 months ago

KALA BIO Transcript: AGM 2026

Jan 26, 2026, 7:00 AM EST - 7 months ago

KALA BIO Proxy statement: Proxy Filing

Jan 6, 2026, 7:00 AM EST - 8 months ago

KALA BIO Proxy statement: Proxy Filing

Jan 5, 2026, 4:10 PM EST - 8 months ago

KALA BIO Settles Approximately $10.6 million of Debt

Dec 30, 2025, 7:00 AM EST - 8 months ago

KALA BIO Proxy statement: Proxy Filing

Dec 19, 2025, 7:00 AM EST - 9 months ago

KALA BIO Proxy statement: Proxy Filing

2025-12-04T15:55:28.000Z - 9 months ago

Kala Bio announces $10M registered direct offering priced at-the-market

Dec 4, 2025, 10:45 AM EST - 9 months ago

KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

2025-12-01T12:11:04.000Z - 9 months ago

Kala Bio enters securities purchase agreement with David Lazar, names him CEO

Nov 19, 2025, 4:00 PM EST - 10 months ago

KALA BIO Quarterly report: Q3 2025

2025-09-30T13:35:26.000Z - 1 year ago

Kala Bio downgraded to Neutral from Outperform at Mizuho

2025-09-29T17:25:13.000Z - 1 year ago

Kala Bio downgraded to Neutral from Buy at H.C. Wainwright

2025-09-29T17:25:08.000Z - 1 year ago

H.C. Wainwright downgrades Kala Bio to Neutral after CHASE trial miss

2025-09-29T15:20:15.000Z - 1 year ago

Kala Bio shared no details on study miss, says Mizuho

2025-09-29T15:15:13.000Z - 1 year ago

Kala Pharmaceuticals downgraded to Market Perform at LifeSci Capital

Sep 10, 2025, 2:00 PM EDT - 1 year ago

KALA BIO Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Aug 13, 2025, 1:00 PM EDT - 1 year ago

KALA BIO Transcript: H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Aug 8, 2025, 8:00 AM EDT - 1 year ago

KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 8, 2025, 8:00 AM EDT - 1 year ago

KALA BIO Quarterly report: Q2 2025

Aug 8, 2025, 8:00 AM EDT - 1 year ago

KALA BIO Earnings release: Q2 2025

Aug 6, 2025, 8:00 AM EDT - 1 year ago

KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Jul 16, 2025, 4:00 PM EDT - 1 year ago

KALA BIO Transcript: Status Update

Jul 16, 2025, 4:00 PM EDT - 1 year ago

KALA BIO Slides: Status Update

Jul 9, 2025, 8:00 AM EDT - 1 year ago

KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)

Jun 5, 2025, 1:25 PM EDT - 1 year ago

KALA BIO Transcript: Jefferies Global Healthcare Conference 2025

May 29, 2025, 8:00 AM EDT - 1 year ago

KALA BIO to Present at Jefferies Global Healthcare Conference

May 14, 2025, 8:00 AM EDT - 1 year ago

KALA BIO Quarterly report: Q1 2025

May 14, 2025, 8:00 AM EDT - 1 year ago

KALA BIO Earnings release: Q1 2025

Mar 31, 2025, 8:00 AM EDT - 1 year ago

KALA BIO Annual report: Q4 2024

Mar 31, 2025, 8:00 AM EDT - 1 year ago

KALA BIO Earnings release: Q4 2024

Mar 5, 2025, 11:50 AM EST - 1 year ago

KALA BIO Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 12, 2025, 8:00 AM EST - 1 year ago

KALA BIO Announces Chief Executive Officer Transition

Jan 24, 2025, 7:00 AM EST - 1 year ago

KALA BIO Registration statement: Registration Filing

Dec 30, 2024, 8:00 AM EST - 1 year ago

KALA BIO Announces $10,750,000 Private Placement

Dec 4, 2024, 11:30 AM EST - 1 year ago

KALA BIO Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 27, 2024, 8:00 AM EST - 1 year ago

KALA BIO to Present at Piper Sandler 36th Annual Healthcare Conference

Nov 12, 2024, 7:00 AM EST - 1 year ago

KALA BIO Quarterly report: Q3 2024

Nov 12, 2024, 7:00 AM EST - 1 year ago

KALA BIO Earnings release: Q3 2024

Aug 15, 2024, 7:00 AM EDT - 2 years ago

KALA BIO Transcript: H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Aug 6, 2024, 7:00 AM EDT - 2 years ago

KALA BIO Quarterly report: Q2 2024

Aug 6, 2024, 7:00 AM EDT - 2 years ago

KALA BIO Earnings release: Q2 2024

Jul 25, 2024, 8:00 AM EDT - 2 years ago

KALA BIO Registration statement: Registration Filing

Jun 5, 2024, 12:30 PM EDT - 2 years ago

KALA BIO Transcript: Jefferies 2024 Global Healthcare Conference

May 30, 2024, 8:00 AM EDT - 2 years ago

KALA BIO Proxy statement: Proxy Filing

May 14, 2024, 4:05 PM EDT - 2 years ago

KALA BIO Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 14, 2024, 4:00 PM EDT - 2 years ago

KALA BIO Quarterly report: Q1 2024

May 14, 2024, 4:00 PM EDT - 2 years ago

KALA BIO Earnings release: Q1 2024

Apr 29, 2024, 8:00 AM EDT - 2 years ago

KALA BIO Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

KALA BIO Proxy statement: Proxy Filing

Apr 19, 2024, 8:00 AM EDT - 2 years ago

KALA BIO Proxy statement: Proxy Filing

Mar 29, 2024, 8:00 AM EDT - 2 years ago

KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Mar 29, 2024, 8:00 AM EDT - 2 years ago

KALA BIO Earnings release: Q4 2023

Mar 29, 2024, 8:00 AM EDT - 2 years ago

KALA BIO Annual report: Q4 2023

Mar 4, 2024, 12:50 PM EST - 2 years ago

KALA BIO Transcript: TD Cowen 44th Annual Health Care Conference 2024

Feb 26, 2024, 8:00 AM EST - 2 years ago

KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference

Feb 13, 2024, 12:00 PM EST - 2 years ago

KALA BIO Transcript: Oppenheimer 34th Annual Healthcare Life Sciences Conference (Virtual)

Jan 19, 2024, 4:01 PM EST - 2 years ago

KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 13, 2023, 8:00 AM EST - 3 years ago

KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 13, 2023, 7:00 AM EST - 3 years ago

KALA BIO Quarterly report: Q3 2023

Nov 13, 2023, 7:00 AM EST - 3 years ago

KALA BIO Earnings release: Q3 2023

Sep 5, 2023, 8:00 AM EDT - 3 years ago

KALA BIO to Present at H.C. Wainwright 25th Annual Global Investment Conference

Aug 4, 2023, 8:00 AM EDT - 3 years ago

KALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 4, 2023, 7:00 AM EDT - 3 years ago

KALA BIO Quarterly report: Q2 2023

Aug 4, 2023, 7:00 AM EDT - 3 years ago

KALA BIO Earnings release: Q2 2023

Aug 2, 2023, 4:01 PM EDT - 3 years ago

KALA BIO to Participate in Upcoming Investor Conferences in August

Jul 19, 2023, 4:01 PM EDT - 3 years ago

Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 2, 2023, 8:00 AM EDT - 3 years ago

Kala Pharmaceuticals to Present at the Jefferies Healthcare Conference

Jun 1, 2023, 8:00 AM EDT - 3 years ago

KALA BIO Proxy statement: Proxy Filing

May 11, 2023, 8:00 AM EDT - 3 years ago

KALA BIO Proxy statement: Proxy Filing

May 9, 2023, 8:00 AM EDT - 3 years ago

Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 9, 2023, 8:00 AM EDT - 3 years ago

KALA BIO Registration statement: Registration Filing

May 9, 2023, 7:00 AM EDT - 3 years ago

KALA BIO Quarterly report: Q1 2023

May 9, 2023, 7:00 AM EDT - 3 years ago

KALA BIO Earnings release: Q1 2023

Apr 28, 2023, 8:00 AM EDT - 3 years ago

Combangio, Inc., a Wholly Owned Subsidiary of Kala Pharmaceuticals, Awarded $15 Million by California Institute for Regenerative Medicine to Support Ongoing KPI-012 Program for the Treatment of PCED

Mar 27, 2023, 8:00 AM EDT - 3 years ago

Kala Pharmaceuticals Announces Positive Safety Update from Cohort 1 of CHASE Phase 2b Clinical Trial Evaluating KPI-012 in Patients with PCED

Mar 13, 2023, 8:00 AM EDT - 3 years ago

KALA BIO Proxy statement: Proxy Filing

Mar 8, 2023, 4:01 PM EST - 3 years ago

Kala Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference

Mar 3, 2023, 8:00 AM EST - 3 years ago

Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Mar 3, 2023, 7:00 AM EST - 3 years ago

KALA BIO Annual report: Q4 2022

Mar 3, 2023, 7:00 AM EST - 3 years ago

KALA BIO Earnings release: Q4 2022

Mar 3, 2023, 7:00 AM EST - 3 years ago

KALA BIO Registration statement: Registration Filing

Mar 3, 2023, 7:00 AM EST - 3 years ago

KALA BIO Registration statement: Registration Filing

Mar 1, 2023, 7:00 AM EST - 3 years ago

KALA BIO Proxy statement: Proxy Filing

Dec 30, 2022, 12:02 PM EST - 3 years ago

Kala Pharmaceuticals stock up 750% in 3 days after upbeat FDA news on PCED treatment

Dec 28, 2022, 6:48 AM EST - 3 years ago

Kala Pharmaceuticals stock rockets after FDA accepts IND application for PCED treatment

Dec 27, 2022, 4:01 PM EST - 4 years ago

Kala Pharmaceuticals Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCED

Nov 28, 2022, 4:02 PM EST - 4 years ago

Kala Pharmaceuticals Announces Submission of Investigational New Drug Application for KPI-012 for the Treatment of Persistent Corneal Epithelial Defect

Nov 28, 2022, 4:01 PM EST - 4 years ago

Kala Pharmaceuticals Announces Up to $31 Million Private Placement Financing

Nov 8, 2022, 8:30 AM EST - 4 years ago

KALA BIO Quarterly report: Q3 2022

Nov 8, 2022, 8:30 AM EST - 4 years ago

KALA BIO Earnings release: Q3 2022

Nov 8, 2022, 8:00 AM EST - 4 years ago

Kala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Nov 1, 2022, 7:30 AM EDT - 4 years ago

Kala Pharmaceuticals Announces Appointment of Marjan Farid, M.D., to its Board of Directors

Oct 20, 2022, 7:30 AM EDT - 4 years ago

Kala Pharmaceuticals Announces Reverse Stock Split

Sep 9, 2022, 8:00 AM EDT - 4 years ago

KALA BIO Proxy statement: Proxy Filing

Sep 6, 2022, 8:00 AM EDT - 4 years ago

Kala Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference

Aug 30, 2022, 8:00 AM EDT - 4 years ago

KALA BIO Proxy statement: Proxy Filing

Aug 19, 2022, 4:01 PM EDT - 4 years ago

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Aug 18, 2022, 4:01 PM EDT - 4 years ago

Kala Pharmaceuticals Announces Distribution of Series D Preferred Stock to Holders of its Common Stock

Aug 11, 2022, 11:15 AM EDT - 4 years ago

KALA BIO Earnings Call Transcript: Q2 2022

Aug 11, 2022, 11:15 AM EDT - 4 years ago

KALA BIO Quarterly report: Q2 2022

Aug 11, 2022, 11:15 AM EDT - 4 years ago

KALA BIO Earnings release: Q2 2022

Aug 11, 2022, 11:15 AM EDT - 4 years ago

KALA BIO Slides: Q2 2022

Aug 11, 2022, 7:00 AM EDT - 4 years ago

Kala Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Aug 4, 2022, 4:01 PM EDT - 4 years ago

Kala Pharmaceuticals to Participate in Upcoming Investor Conferences in August

Jul 11, 2022, 8:00 AM EDT - 4 years ago

Kala Pharmaceuticals Completes Sale of EYSUVIS® and INVELTYS® to Alcon Inc

Jun 2, 2022, 8:00 AM EDT - 4 years ago

Kala Pharmaceuticals to Present at Jefferies Healthcare Conference

May 31, 2022, 8:00 AM EDT - 4 years ago

KALA BIO Proxy statement: Proxy Filing

May 23, 2022, 12:01 AM EDT - 4 years ago

Kala Announces Entry into Definitive Agreement to Sell EYSUVIS® and INVELTYS® to Alcon Inc.

MrTicker Sep. 1 at 9:52 PM

0 · Reply

MrTicker Sep. 1 at 9:51 PM

$KALA on the move

0 · Reply

RTPRwire Sep. 1 at 9:36 PM

0 · Reply

Nibbler Sep. 1 at 6:13 PM

$KALA Why it is down?

0 · Reply

Gymlover Sep. 1 at 3:58 PM

$KALA it’s going to short squeeze 👀 👀

1 · Reply

Kennyk93 Sep. 1 at 2:38 PM

$KALA added

0 · Reply

Ozyil Sep. 1 at 2:34 PM

$KALA i forgot buy dip at opening, i will wait for next dip

0 · Reply

SwingTrader34 Sep. 1 at 1:19 PM

$KALA seems like they will dump it today. i am out with a small loss

0 · Reply

SwingTrader34 Sep. 1 at 12:52 PM

$KALA These mfers are so greedy that they don't let go any opportunity to dilute the shareholders.

0 · Reply

Skimman Sep. 1 at 12:48 PM

$KALA Bullshit Company

0 · Reply

MrAlientrader Sep. 1 at 12:42 PM

$KALA very strange stock, there are big sellers keep feeding shares. Not sure where are so many shares from. Anyway, the atock is fully controlled by shorts so no pont to list it or buy any shares, just get it delisted good for all

0 · Reply

Gymlover Sep. 1 at 12:32 PM

$KALA loading zone to make profit.i added more

0 · Reply

Gymlover Sep. 1 at 12:31 PM

$KALA it will bounce back.news is bullish.

0 · Reply

Skimman Sep. 1 at 12:31 PM

$KALA no news and u open up.at .67... WHAT A JOKE

0 · Reply

Skimman Sep. 1 at 12:28 PM

$KALA DELIST IT

0 · Reply

Skimman Sep. 1 at 12:23 PM

$KALA why are u even PUBLICLY LISTED...TRASH

0 · Reply

Skimman Sep. 1 at 12:22 PM

$KALA TRASH

0 · Reply

Skimman Sep. 1 at 12:18 PM

$KALA DISTGUSTING

0 · Reply

Skimman Sep. 1 at 12:03 PM

$KALA just close. Cause your JUNK ... OBVIOUSLY

0 · Reply

Skimman Sep. 1 at 12:02 PM

$KALA a shitty company...has news and drops...COMPLETE JUNK...haha

0 · Reply

Rachel20201 Sep. 1 at 12:02 PM

$KALA Short Shares Availability

0 · Reply

Rachel20201 Sep. 1 at 12:00 PM

$KALA Short Shares Availability

0 · Reply

Market Cap	13.35M
Revenue (ttm)	0.00
Net Income (ttm)	-26.98M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	9,048,199
Avg Vol	168,624
Day's Range	N/A - N/A
Shares Out	19.34M
Stochastic %K	17%
Beta	-2.26
Analysts	Strong Buy
Price Target	$1.50